Skye Bioscience, Inc. (SKYE)
Automate Your Wheel Strategy on SKYE
With Tiblio's Option Bot, you can configure your own wheel strategy including SKYE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SKYE
- Rev/Share 0.0
- Book/Share 1.1013
- PB 1.1895
- Debt/Equity 0.0084
- CurrentRatio 6.0857
- ROIC -1.1397
- MktCap 41977425.0
- FreeCF/Share -0.8811
- PFCF -1.2013
- PE -1.2261
- Debt/Assets 0.007
- DivYield 0
- ROE -0.6865
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SKYE | Cantor Fitzgerald | Overweight | Neutral | -- | $2 | Oct. 6, 2025 |
| Downgrade | SKYE | Craig Hallum | Buy | Hold | -- | $2 | Oct. 6, 2025 |
| Initiation | SKYE | Evercore ISI | -- | Outperform | -- | $10 | Aug. 15, 2025 |
| Initiation | SKYE | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | SKYE | Scotiabank | -- | Sector Outperform | -- | $20 | Sept. 30, 2024 |
| Initiation | SKYE | JMP Securities | -- | Mkt Outperform | -- | $15 | Sept. 10, 2024 |
News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period").
Read More
SKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases.
Read More
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Alleg.
Read More
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Skye Bioscience, Inc.Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose key facts, including allegations that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Read More
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. (SKYE)
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Skye Bioscience, Inc. (“Syke” or the “Company”) (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”).
Read More
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
Read More
Skye Bioscience, Inc. - Special Call
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Skye Bioscience, Inc. - Special Call Company Participants Bernie Hertel Punit Dhillon - President, CEO, Secretary & Director Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Christopher Twitty - Chief Scientific Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Louis Aronne Michael DiFiore - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Sean Wharton Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Ananda Ghosh …
Read More
Skye Bioscience: Promising Nimacimab Data Supports Buy Rating
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Positive
Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing potential as monotherapy, combination, or maintenance therapy, with favorable early data. Risks include clinical trial uncertainties, manufacturing reliance, and regulatory scrutiny, but SKYE's cash runway extends through Q1 2027, supporting key milestones.
Read More
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Skye Bioscience, Inc. (NASDAQ:SKYE ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Punit Dhillon - President, CEO, Secretary & Director Conference Call Participants Frank Tang - Morgan Stanley Presentation Frank Tang Managing Director Good morning, everyone. My name is Frank Tang, and I'm with the Investment Banking division at Morgan Stanley.
Read More
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025
Read More
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
Read More
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
About Skye Bioscience, Inc. (SKYE)
- IPO Date 2014-11-26
- Website https://skyebioscience.com
- Industry Biotechnology
- CEO Punit S. Dhillon
- Employees 16